John Lauriello, MD

  • 16Articles
  • 116.2KReads
  • 1999–2022Active
  • 32Collaborators
  • 501Citations

About

John Lauriello, MD is affiliated with Department of Psychiatry and Human Behavior, Thomas Jefferson University, Philadelphia, Pennsylvania. John Lauriello has authored or co-authored 16 peer-reviewed articles published across the Journal of Clinical Psychiatry and the Primary Care Companion for CNS Disorders between 1999 and 2022. Their work focuses on Schizophrenia/Schizoaffective Disorders, Sexual Dysfunction, Psychiatry, and Psychotherapy.

Publications

JCP
Sublingual Dexmedetomidine for Agitation in Schizophrenia
Original Research

Sublingual Dexmedetomidine for Agitation in Schizophrenia

October 3, 2022

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or schizoaffective disorder.
, , , et al
JCP
Original Research

Long-Term Safety of Aripiprazole Lauroxil

August 18, 2020

Long-acting injectable (LAI) antipsychotics improve adherence, reduce treatment gaps, and improve clinical outcomes. This report describes the long-term safety, tolerability, and symptom trajectory with the LAI antipsychotic aripiprazole lauroxil.
, , , et al
JCP
Academic Highlights

Schizophrenia Remission Roller Coaster

June 30, 2020

In this journal CME activity, find experts' recommendations for reducing schizophrenia relapse, such as adopting a patient-centered approach, selecting medications based on current evidence, and implementing psychosocial interventions.
,
JCP
Educational Activity

Patient-Centered Care for Schizophrenia

May 12, 2020

You can help your patients with schizophrenia achieve the ultimate goal of treatment—recovery. Learn how to use patient-centered care to enhance medication adherence and aid functional recovery.
JCP
Educational Activity

Prevalence and Impact of Schizophrenia Relapse

March 24, 2020

What can you do to combat relapse in your patients with schizophrenia? Dr Lauriello discusses identifying and addressing a major contributor to relapse—nonadherence to antipsychotics.
JCP
Educational Activity

Improving Adherence to Schizophrenia Treatment

March 26, 2019

Relapse of schizophrenia often occurs due to treatment nonadherence. Long-acting injectable (LAI) antipsychotics can improve adherence but are underused. Watch this Webcast to hear interviews with patients and learn...
,
JCP
Academic Highlights

Continuous Care for Schizophrenia

February 19, 2019

Even brief interruptions in treatment can significantly increase a schizophrenia patient's risk of psychotic relapse. Read this Academic Highlights to discover the complex factors that can contribute to treatment...
,
JCP
Educational Activity

Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?

February 21, 2018

Long-acting injectable (LAI) antipsychotics have the potential to improve adherence and outcomes for patients with serious mental illness but are underused. Watch this Webcast to learn how to identify...
,
JCP
Letter to the Editor

Dr Correll and Colleagues Reply

October 25, 2017

, , , et al
JCP
Supplement Article

Injectable Antipsychotics in Schizophrenia

September 30, 2016

Read the recommendations of experts on the use of long-acting injectable antipsychotic medications in patients with schizophrenia.
, , , et al
JCP
Commentary

Do Long-Term Side Effects Matter? Evaluating the Risk of Hip Fracture in Subjects With Schizophrenia Over a Decade

September 23, 2015

,
JCP
Commentary

Does Indication Drive Use, or Does Use Drive Indication?

March 25, 2015

, ,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe